Literature DB >> 3730407

Uptake by neuroblastoma cells of glucosylceramide, glucosylceramide glucosidase, its stimulator protein, and phosphatidylserine.

S C Datta, R M Snider, N S Radin.   

Abstract

Serum-free cultured neuroblastoma cells (clone NlE-115) have been shown to absorb emulsified glucosylceramide, glucosylceramide glucosidase, an activator protein for the enzyme, and phosphatidylserine from a synthetic medium. Uptake of the enzyme was augmented by phosphatidylserine, and vice versa. Uptake of the enzyme-lipid complex was further augmented by the activator protein. It appears likely that the activator forms a complex only with the enzyme-lipid complex, not with the individual components. Two uptake mechanisms for the enzyme seem to be involved, one of which (the complex with activator proteins and acidic lipid) is sensitive to mannosyl phosphate groups. Hydrolysis of absorbed glucosylceramide was slow unless the medium was supplemented with the acidic phospholipid or glucosidase. The most rapid disappearance of stored glycolipid took place when the ternary mixture was added to the cell medium, enzyme + activator protein + phosphatidylserine. These findings may be relevant to enzyme replacement therapy for Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3730407     DOI: 10.1016/0005-2760(86)90204-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Enzyme-replacement therapy: problems and prospects.

Authors:  B Rademaker; J Raber
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  Subcellular biosynthesis and transport of gangliosides formed from exogenous lactosylceramide in rat liver.

Authors:  M Trinchera; R Ghidoni
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

3.  Heat-stable protein that stimulates acid alpha-glucosidase.

Authors:  N S Radin; A Shukla; G S Shukla; A Sano
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

4.  Distribution of saposin proteins (sphingolipid activator proteins) in lysosomal storage and other diseases.

Authors:  S Morimoto; Y Yamamoto; J S O'Brien; Y Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 5.  Treatment of Gaucher disease with an enzyme inhibitor.

Authors:  N S Radin
Journal:  Glycoconj J       Date:  1996-04       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.